Published in
Russian Journal of Cardiology, 5(25), p. 3919, 2020
DOI: 10.15829/1560-4071-2020-3919
Links
Tools
Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement
Journal article published in 2020 by
S. N. Tereshchenko 
,
M. V. Shestakova ,
F. T. Ageev ,
G. R. Galstyan ,
A. S. Galyavich ,
M. G. Glezer ,
I. V. Zhirov ,
Y.-U. A. Karpov ,
Y. A. Karpov,
Z.-H. D. Kobalava ,
Z. D. Kobalava,
S. T. Matskeplishvili
,
M. V. Shestakova ,
F. T. Ageev ,
G. R. Galstyan ,
A. S. Galyavich ,
M. G. Glezer ,
I. V. Zhirov ,
Y.-U. A. Karpov ,
Y. A. Karpov,
Z.-H. D. Kobalava ,
Z. D. Kobalava,
S. T. Matskeplishvili
